Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer

The aim of this study was to determine the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT) of weekly Irinotecan (CPT-11) plus UFT, and t o assess the antitumour activity of this combination as second-line chemoth erapy in patients with advanced colorectal carcinoma, 31 patients with meas urable advanced colorectal carcinoma were treated. Cohorts of 3 patients re ceived increasing dose levels of the combination. Levels 1 to 4 included a fixed dose of oral (p.o.) UFT (250 mg/m(2)/day) for 21 days of a 28-day cyc le combined with increasing intravenous (i.v.) doses of CPT-11 (80, 100, 11 0 and 120 mg/m(2)) on days 1, 8 and 15. Levels 5 and 6 included a higher fi xed dose of oral UFT (300 mg/m(2)) combined with increasing i.v. doses of C PT-11 (100 and 110 mg/m(2)) on days 1, 8 and 15. 147 courses were administe red. MTD were reached at level 4 (2 cases of grade 4 diarrhoea and 1 grade 3 asthenia), and level 6 (1 grade 4 diarrhoea, 1 grade 3 diarrhoea and 1 gr ade 3 febrile neutropenia). Responses in 30 evaluable patients were: 3 part ial responses (10%), 15 stable disease (50%) and progressive disease in 12 patients (40%). Median time to progression was 4.5 months (95% Confidence I nterval (CI): 3.4-6.6 months) and median survival was 11 months (95% CI: 7. 9-14.1 months). The recommended doses for phase II trials are: (a) CPT-I 1 110 mg/m(2) i.v. on days 1, 8 and 15 every 28 days plus UFT 250 mg/m(2) p.o . on days 1 through to 21 or (b) CPT-11 100 mg/m(2) and UFT 300 mg/m(2). (C ) 2001 Published by Elsevier Science Ltd. All rights reserved.